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ABSTRACT
Healthcare is one of the most promising areas for machine learning models to
make a positive impact. However, successful adoption of AI-based systems in
healthcare depends on engaging and educating stakeholders from diverse back-
grounds about the development process of AI models. We present a broadly ac-
cessible overview of the development life cycle of clinical AI models that is gen-
eral enough to be adapted to most machine learning projects, and then give an
in-depth case study of the development process of a deep learning based system
to detect aortic aneurysms in Computed Tomography (CT) exams. We hope other
healthcare institutions and clinical practitioners find the insights we share about
the development process useful in informing their own model development efforts
and to increase the likelihood of successful deployment and integration of AI in
healthcare.
1 INTRODUCTION
The field of machine learning (ML) has the potential to fundamentally improve healthcare systems
by capitalizing on the advances of deep learning in computer vision, natural language processing,
and speech recognition, facilitated by the increasing accumulation of medical data and the widening
availability of computing resources (Krizhevsky et al., 2012; Devlin et al., 2019; Chorowski et al.,
2015). There continues to be an increasing amount of research in using models to predict dis-
eases, detect biomarkers, improve patient triage, decrease diagnosis time, facilitate novel drug dis-
covery, and optimize hospital operations (Fauw et al., 2018; Esteva et al., 2019; Dana et al., 2018;
Putin et al., 2016; Annarumma et al., 2019). However, in spite of all this promising research, a di-
vide remains between model development and successfully translating results into actual clinical
application. Machine learning in healthcare differs from many other domains, in that labeled data is
extremely expensive to obtain as it must be labeled by clinicians and deployment to legacy hospital
systems requires tight vendor integration in a highly regulated environment. Clinicians should criti-
cally and carefully assess AI applications, as many previous attempts (e.g. expert systems and IBM
Watson), have had difficulty meeting initial expectations in medicine (Heathfield, 1999; Strickland,
2019).
For clinical AI to be adopted successfully, working processes need to be formalized to help mitigate
risk while developing AI-related projects; however, existing project methodologies from software
engineering are difficult to adapt to clinical ML projects, which are more similar to applied research
projects, where progress and final deliverables are difficult to estimate a priori. Model development
is an iterative process which depends heavily on prototypes, experimentations, and constant interac-
tion with clinical expertise to guide and interpret results. To our knowledge, there is a lack of existing
work that focuses on a task-agnostic ML model development framework for clinical applications in
healthcare systems.
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By detailing our clinical AI development process and extrapolating common differentiators of suc-
cessful projects, we hope other organizations can incorporate useful aspects to bridge the gap be-
tween machine learning and clinical utility. In the following sections, we first present a detailed
overview of the development cycle for clinical AI projects aimed at a broad audience and then give
a model development case study of a project to detect aortic aneurysms.
2 THE CLINICAL AI DEVELOPMENT CYCLE
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Figure 1: The clinical AI model development cycle.
2.1 FEASIBILITY AND IMPACT ASSESSMENT OF PROJECT
Before undertaking any development efforts, a proposed project should be evaluated for feasibility,
scope, and clinical impact. Representatives from all stakeholders including clinical, technical, and
commercial teams should be present to establish reasonable goals and timelines for the project.
Potential projects should have a clear, well-defined clinical use case for the model’s application. In
our experience, most project proposals do not pass the feasibility and impact assessment stage. A
common reason why a project is not undertaken is due to insufficient data resources, either lacking
the quantity or quality to train a performant model. Other projects may receive a low priority if
the clinical impact is too narrow or limited in scope, such as a model to predict rare or non-critical
conditions.
If a project is deemed feasible and impactful, important design decisions must be formalized that
will impact the rest of the development cycle. Considerations at this stage can include defining valid
inputs to the model, choosing what labels to collect or annotations to perform, strategies for clinical
evaluation, aligning expectations on timelines, and defining the acceptance criteria.
2.2 DATA ACQUISITION, COHORT SELECTION, AND DATA CLEANING
Once the feasibility and impact of a project has been assessed, the first step for most projects is
the collection and aggregation of data resources. Within a healthcare system, several teams must
coordinate and take measures to ensure that Protected Health information (PHI) is safeguarded and
privacy is maintained. This may require de-identification of medical data and obtaining the requisite
permissions and approvals from human research committees and Institutional Review Boards (IRB).
After the bulk data is acquired, a cohort must be selected while considering multiple factors such
as patient demographics, exclusion criteria, and even characteristics of the data acquisition process
itself. Especially in medical data, a long tail of outlying edge cases may need to be excluded, and
qualifications may need to be placed as to what is considered valid for the model to accept as input.
Biases in the data acquisition process itself can also create issues during model development and
evaluation. For example, in one of our projects to detect stroke in CT, we realized that an imbalance
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in our dataset acquired through imaging scanners of two different manufactures caused the model
to make negative predictions 50%-50% but output positive predictions 95%-5% skewed towards
the predominant manufacture! This examples highlights the need to balance multiple factors of the
training dataset to learn a model that generalizes properly across varying data sources. Determining
more subtle parameters of the data will usually require the domain expertise of a clinician.
Once data is acquired and a cohort is created, additional processing, cleaning, normalization, and
inspection of the data is done to standardize the format before annotating the data and training the
model. These tasks might comprise of imputing missing data, correcting erroneous data, resolving
inconsistencies in data, filtering extraneous data, excluding outliers in the data, and checking the
data for quality assurance and correctness.
2.3 DATA ANNOTATION AND LABELING
For any supervised learning task, the dataset must have accompanying labels to train a model and
to evaluate performance. Determining the type and granularity of labeling depends on the clinical
use case and model learning task. Sometimes, it is possible to leverage passive annotation meth-
ods to extract labels from existing structured data such as parsing ICD-10 medical codes or using
natural language processing to retrieve relevant keywords in the patient reports. Otherwise manual
annotations must be collected.
One unique aspect of developing clinical AI models is that annotation cannot typically be done
without considerable domain expertise and training, such as identifying Ventricular Tachycardia in
Electrocardiograms (ECG) data or localizing Large Vessel Occlusions in CT Angiograms. Exam-
ples of other annotation tasks can include identifying abnormal conditions or events, measuring the
volume of anatomical structures, and placing or drawing markers (points, bounding boxes, poly-
gons) around regions of interest. While being considerate of the clinician’s time, medical image
annotation is often a resource-intensive bottleneck in the model development cycle.
We recommend performing a trial of annotating a small subset of the dataset to check for consis-
tency and correctness among annotators before annotating the entire dataset. In our experience,
capturing excellent annotations will prevent many issues downstream in the development process
as poor annotations lead to a subpar model and difficulties in evaluating model performance on the
ground truth. If possible, ambiguous or difficult cases should have multiple annotators to ensure
consistent ground truth labels. Trials to measure inter-annotator variability could also be conducted
as clinicians may interpret the same case differently due to differences in training, expertise, and
other factors.
2.4 MODEL EXPLORATION, DEVELOPMENT, AND TRAINING
Once annotations are complete, the labeled dataset should be split into training and validation sets
for development of the model and a test set for final evaluation of the model. A baseline model will
first be developed to gauge the difficulty of the problem and give some indication of the performance
improvement necessary to reach the acceptance criteria. When a baseline has been established, ef-
forts can be made to improve the model’s performance through changing the model architecture,
further data processing, feature engineering, data augmentation strategies, model ensembling tech-
niques, and hyper-parameter tuning. In practice, we found that engineering effort is usually well
spent on developing a robust data processing pipeline and focusing on techniques to increase signal
to the model, for example registering the skull to a standard atlas and skull-stripping before feeding
into an inter-cranial stroke classification model.
Other model design decisions are driven by specifications of the clinical use case. In some cases,
even if a model does not attain high performance on some metrics, it may still provide clinical utility
(e.g. clinical workflow improvements), while models with higher performance may not actually be
clinically useful if they are not robust to variations in the data distribution or require extremely
long inference times. Also, some types of errors are more egregious than others for the clinical
application, and the use case should inform model development priorities, such as setting the ROC
operating point for the appropriate sensitivity versus specificity of a classifier.
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2.5 MODEL TESTING AND CLINICAL EVALUATION
After a model has been trained and meets the performance metrics on the validation set, it can be
evaluated on the holdout test set as a measure of its ability to generalize on the unseen data (i.e.
true data distribution). Crucially, once a test set has been evaluated, an additional test set must be
collected for further development to avoid model bias. If a large discrepancy exists between the
performance on the validation set and the test set, it may be due to data leakage (when information
about the validation set is passed to the model, which results in an overestimation of the model’s
generalizability) or the test set having a disparate distribution from the validation set, which can
occur with small samples sizes or when the dataset was not stratified properly. Care must be taken
to ensure that multiple images or data points for the same patient do not cross between training,
validation, and test sets. In cases where the dataset is extremely limited or imbalanced, other data
partitioning schemes such as k-fold cross validation or stratified sampling can be applied.
Besides measuring performance metrics, the results of the model’s predictions should also be clin-
ically evaluated for failure modes and clinical mimics. An analysis of the types and frequencies of
prediction errors may reveal interesting insights about the dataset or labels, such as incorrect ground
truth, corrupted data, or hidden biases in the data cohort, that can used to improve the model or
adjust the clinical use case. Inter-clinician experiments can also be conducted to measure agreement
between the model and the clinician as well as agreement between clinicians.
2.6 ACCEPTANCE, TERMINATION, OR ITERATION
If the model does not meet the performance requirements of the clinical use case and development
cannot continue, the project may terminate at this stage, in which case a post mortem of the life
cycle can be conducted. If the model meets performance criteria and is accepted into the deploy-
ment cycle, next steps can include additional clinical evaluation such as external off-site validation,
conducting clinical trials to submit for FDA approval, or gathering application feedback in a clinical
environment. Often, projects continue iterating into previous stages multiple times during the course
of a project.
3 AORTIC ANEURYSM MODEL CASE STUDY
Aortic aneurysms are abnormal enlargements in the wall of the aorta, the major blood vessel that
connects the heart to the rest of the body, which can fatally rupture with a 90% mortality rate if
left untreated. Because most aneurysms are asymptomatic until rupturing and identified inciden-
tally only 65% of time, there is clinical utility in developing a model to automatically detect aortic
aneurysms on routine chest and abdominal CT examinations Claridge et al. (2017). The clinical
definition for aortic aneurysms is based on the measurement of the largest diameter of the aorta, so
the model has to perform several subtasks (segmentation, measurement, classification) to produce
the needed outputs for clinical application. Our project proceeded through three iterations of the
development life cycle detailed below.
Assess project Collect data Annotate Train model Evaluate
Collect more dataAnnotate dataTrain modelEvaluate
Annotate data Train model Evaluate Accept model
Figure 2: The aortic aneurysm model life cycle. Colors correspond to development iteration.
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3.1 FIRST ITERATION
After the clinical use case was defined and project investigators obtained IRB approval, a data acqui-
sition pull was requested for 1000 contrast and non-contrast CT examinations of the chest, abdomen,
and pelvis that matched keywords relating to aortic aneurysms in the radiological patient reports. Af-
ter the data was pulled, the raw patient-level data had to be filtered to contain only the appropriate
examination-level images for each patient as an individual patient often has multiple examinations.
Exams were further filtered by acquisition parameters of the imaging scanner, such as slice thickness
and number of slices in an exam. This selection process was only partially automated as examination
metadata is not always reliable and often missing or incorrect. Manual inspection for image quality
and confirmation of the presence of aneurysm was also performed by radiologists. Overall, this data
curation process took several months before annotations could start.
For purposes of visualization and aneurysm measurement, annotations consisted of volumetric 3D
segmentation masks of the entire aorta, including the any present aneurysms or pseudo-aneurysms.
Other labels, including the location and diameter measurement of the aneurysm, were extracted
from the radiological report data. Manually segmenting the aorta is a time consuming but not a very
clinically challenging task, so an external party of medically trained annotators were used, which
required de-identification of all PHI in the examination data.
The primary model architecture was a 3D U-Net-like model, similar to C¸ic¸ek et al. (2016), to output
a segmentation prediction of the abdominal aorta from abdominal-pelvic CT exams. This predicted
segmentation volume was post-processed and an ellipse fitting algorithm extracted the maximal
diameter perpendicular to the centerline axis of the aorta. See our paper Lu et al. (2019) for more
information. The abdominal model achieved good performance on the test set with Dice score of
0.9, sensitivity of 91%, and specificity of 95%. This development iteration required 9 months.
3.2 SECOND ITERATION
Secondary development of a model to detect thoracic aortic aneurysms using a similar approach
proved to be much more difficult as the thoracic aorta curves in a cane-like shape through the chest
cavity while the abdominal aorta is predominately straight. Upon review of the segmentation annota-
tions of the thoracic aorta, we uncovered quality issues, including missing sections of the segmented
aorta, over-annotation of the aortic root, and under-annotation of the aortic arch. To address these
annotation quality issues, we collected a new batch of data to annotate with additional training of the
annotators to ensure a better standard level of quality. This added 3 additional months to the project
timeline.
After the new annotations were complete, an expert clinician at our institution checked the anno-
tations for quality and made minor corrections. Additional engineering effort was devoted to new
morphological processing and angle correction algorithms to extract the correct diameter measure-
ments from the thoracic aorta segmentations. These diameter measurements would be used to train
an ensemble classifier for a final prediction. The combination of higher quality segmentation labels,
improved post-processing transformations, and additional classification model led to evaluation per-
formance that exceeded the acceptance criteria with a Dice score of 0.93, sensitivity of 96%, and
specificity of 95%.
3.3 THIRD ITERATION
A final iteration cycle was needed to develop a model to delineate the boundary between thorax
and abdomen during inference time to route the appropriate CT exam to the correct segmentation
model. Annotations were reasonably cheap as only a slice-level label denoting the boundary was
needed for each exam. A model based off the ResNet architecture from He et al. (2016) was trained
to regress slice-level and output a scalar value predicting the distance from the boundary. Then,
portions of the image containing the thoracic aorta would be sent the thoracic model while sections
of the abdominal aorta would be sent to the abdominal model for prediction.
After clinical evaluation and alpha testing of 1000 additional retrospective cases, all models and
their dependencies were packaged to be integrated into existing clinical workflow software. With
integration complete, a beta test in a clinical environment was scheduled before wider deployment.
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A THE DEPLOYMENT CYCLE
While we focusedmainly on the development cycle, we briefly discuss the deployment cycle. Once a
model has been through evaluation and met the acceptance criteria, the model must be packaged and
ingested in an inference system to be integrated into the clinician workflow. This process can be quite
involved and domain specific depending on the inference platform and integration requirements for
existing point-of-care software and database systems, often requiring coordination between several
external vendors and regulatory committees.
For some of our projects, the next phase after model development is shadow inference, where the
model runs inference on live data streams but does not impact clinical decision making. Shadow
inference is performed to test system integration and gather feedback on the clinical application.
Ongoing efforts are made to interface with clinicians to develop standards for deployment of clinical
AI applications. Other important considerations of model deployment include continual monitoring
for different failure modes and distribution shifts in non-stationary data. As clinical decisions are
influence by models predictions, models will need to be continuously evaluated, recalibrated, and
retrained on new data as the population changes over time. Other interesting work around model de-
ployment includes federated learning, clinician-machine interfaces, and active learning techniques.
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